Group 1 - The FDA issued a warning letter to Novo Nordisk regarding misleading advertisements for its oral weight loss drug, semaglutide, suggesting that the drug's effects are superior to other approved GLP-1 weight loss medications [1] - The FDA's letter indicated that the advertisements misleadingly implied that the drug could provide benefits beyond weight loss, such as emotional relief and life direction, which have not been substantiated [1] - The FDA also noted that the advertisements failed to adequately disclose risk information as required, demanding that the company take immediate corrective action, including ceasing all misleading advertisements [1] Group 2 - Novo Nordisk responded by stating that it would take the feedback from regulatory agencies seriously and address their concerns regarding the advertisement presentation [2] - It is noteworthy that in September of the previous year, the FDA had issued warning letters to multiple companies, including Novo Nordisk and Eli Lilly, regarding their promotion of weight loss drugs, highlighting issues such as downplaying risks and failing to submit advertising materials for review [2]